Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: From risk factors to disease modulators

Barbara Borroni, Silvana Archetti, Chiara Agosti, Nabil Akkawi, Cristina Brambilla, Luigi Caimi, Carlo Caltagirone, Monica Di Luca, Alessandro Padovani

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Increasing biological and clinical findings argue for a link between brain cholesterol turnover and Alzheimer Disease (AD), high cerebral levels of the former increasing Aβ load. Cerebral cholesterol elimination involves two mechanisms dependent on Apolipoprotein E (ApoE) and cholesterol 24-hydroxylase (CYP46). The aim of this study was to evaluate an intronic variation in CYP46 (intron 2, T→C) along with ApoE genotype as risk factors for AD and to establish the correlation between CYP46/ApoE polymorphism and disease progression. One-hundred and fifty-seven AD patients, who had been followed periodically through 1-year follow-up after enrolment, and 134 age- and gender-matched controls entered the study. The distribution of CYP46 genotypes was significantly different in AD compared to controls (P*C allele higher in AD patients (P*C carriers was 2.8, and in ApoE ε4 carriers was 4.05; the OR for having both CYP46 *C and ApoE ε4 was 17.75, demonstrating the their synergic effect on AD risk. In AD patients, CYP46*C along with ApoE ε4 genotype were associated with a higher cognitive decline at 1-year follow-up (P

Original languageEnglish
Pages (from-to)747-751
Number of pages5
JournalNeurobiology of Aging
Volume25
Issue number6
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Apolipoproteins E
Alzheimer Disease
Genotype
Apolipoprotein E4
Cholesterol
Cytochrome P450 Family 46
Introns
Disease Progression
Alleles
Brain

Keywords

  • Alzheimer Disease
  • ApoE
  • CYP46
  • Rate of cognitive decline
  • Risk factors

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)

Cite this

Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease : From risk factors to disease modulators. / Borroni, Barbara; Archetti, Silvana; Agosti, Chiara; Akkawi, Nabil; Brambilla, Cristina; Caimi, Luigi; Caltagirone, Carlo; Di Luca, Monica; Padovani, Alessandro.

In: Neurobiology of Aging, Vol. 25, No. 6, 07.2004, p. 747-751.

Research output: Contribution to journalArticle

Borroni, Barbara ; Archetti, Silvana ; Agosti, Chiara ; Akkawi, Nabil ; Brambilla, Cristina ; Caimi, Luigi ; Caltagirone, Carlo ; Di Luca, Monica ; Padovani, Alessandro. / Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease : From risk factors to disease modulators. In: Neurobiology of Aging. 2004 ; Vol. 25, No. 6. pp. 747-751.
@article{19c17bf0fd394c0ba61d2791a774ecf5,
title = "Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: From risk factors to disease modulators",
abstract = "Increasing biological and clinical findings argue for a link between brain cholesterol turnover and Alzheimer Disease (AD), high cerebral levels of the former increasing Aβ load. Cerebral cholesterol elimination involves two mechanisms dependent on Apolipoprotein E (ApoE) and cholesterol 24-hydroxylase (CYP46). The aim of this study was to evaluate an intronic variation in CYP46 (intron 2, T→C) along with ApoE genotype as risk factors for AD and to establish the correlation between CYP46/ApoE polymorphism and disease progression. One-hundred and fifty-seven AD patients, who had been followed periodically through 1-year follow-up after enrolment, and 134 age- and gender-matched controls entered the study. The distribution of CYP46 genotypes was significantly different in AD compared to controls (P*C allele higher in AD patients (P*C carriers was 2.8, and in ApoE ε4 carriers was 4.05; the OR for having both CYP46 *C and ApoE ε4 was 17.75, demonstrating the their synergic effect on AD risk. In AD patients, CYP46*C along with ApoE ε4 genotype were associated with a higher cognitive decline at 1-year follow-up (P",
keywords = "Alzheimer Disease, ApoE, CYP46, Rate of cognitive decline, Risk factors",
author = "Barbara Borroni and Silvana Archetti and Chiara Agosti and Nabil Akkawi and Cristina Brambilla and Luigi Caimi and Carlo Caltagirone and {Di Luca}, Monica and Alessandro Padovani",
year = "2004",
month = "7",
doi = "10.1016/j.neurobiolaging.2003.08.004",
language = "English",
volume = "25",
pages = "747--751",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease

T2 - From risk factors to disease modulators

AU - Borroni, Barbara

AU - Archetti, Silvana

AU - Agosti, Chiara

AU - Akkawi, Nabil

AU - Brambilla, Cristina

AU - Caimi, Luigi

AU - Caltagirone, Carlo

AU - Di Luca, Monica

AU - Padovani, Alessandro

PY - 2004/7

Y1 - 2004/7

N2 - Increasing biological and clinical findings argue for a link between brain cholesterol turnover and Alzheimer Disease (AD), high cerebral levels of the former increasing Aβ load. Cerebral cholesterol elimination involves two mechanisms dependent on Apolipoprotein E (ApoE) and cholesterol 24-hydroxylase (CYP46). The aim of this study was to evaluate an intronic variation in CYP46 (intron 2, T→C) along with ApoE genotype as risk factors for AD and to establish the correlation between CYP46/ApoE polymorphism and disease progression. One-hundred and fifty-seven AD patients, who had been followed periodically through 1-year follow-up after enrolment, and 134 age- and gender-matched controls entered the study. The distribution of CYP46 genotypes was significantly different in AD compared to controls (P*C allele higher in AD patients (P*C carriers was 2.8, and in ApoE ε4 carriers was 4.05; the OR for having both CYP46 *C and ApoE ε4 was 17.75, demonstrating the their synergic effect on AD risk. In AD patients, CYP46*C along with ApoE ε4 genotype were associated with a higher cognitive decline at 1-year follow-up (P

AB - Increasing biological and clinical findings argue for a link between brain cholesterol turnover and Alzheimer Disease (AD), high cerebral levels of the former increasing Aβ load. Cerebral cholesterol elimination involves two mechanisms dependent on Apolipoprotein E (ApoE) and cholesterol 24-hydroxylase (CYP46). The aim of this study was to evaluate an intronic variation in CYP46 (intron 2, T→C) along with ApoE genotype as risk factors for AD and to establish the correlation between CYP46/ApoE polymorphism and disease progression. One-hundred and fifty-seven AD patients, who had been followed periodically through 1-year follow-up after enrolment, and 134 age- and gender-matched controls entered the study. The distribution of CYP46 genotypes was significantly different in AD compared to controls (P*C allele higher in AD patients (P*C carriers was 2.8, and in ApoE ε4 carriers was 4.05; the OR for having both CYP46 *C and ApoE ε4 was 17.75, demonstrating the their synergic effect on AD risk. In AD patients, CYP46*C along with ApoE ε4 genotype were associated with a higher cognitive decline at 1-year follow-up (P

KW - Alzheimer Disease

KW - ApoE

KW - CYP46

KW - Rate of cognitive decline

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=2542523048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542523048&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2003.08.004

DO - 10.1016/j.neurobiolaging.2003.08.004

M3 - Article

C2 - 15165699

AN - SCOPUS:2542523048

VL - 25

SP - 747

EP - 751

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 6

ER -